Disclosures for "Phase I Analysis of DOC1021, A Cell-based Vaccination Platform for Adjuvant Therapy of Glioblastoma"
-
Dr. Zhu has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novocure, INC, Japan. An immediate family member of Dr. Zhu has stock in Abbott lab. The institution of Dr. Zhu has received research support from NRG NIH. The institution of Dr. Zhu has received research support from Novocure, Inc. The institution of Dr. Zhu has received research support from Five Prime pharmaceutical. The institution of Dr. Zhu has received research support from Denovo, inc. The institution of Dr. Zhu has received research support from Boston Biomedical Sumitomo Dainippon Pharma Global Oncology. The institution of Dr. Zhu has received research support from CNS pharmaceutical. The institution of Dr. Zhu has received research support from ABM Therapeutics Corporation . The institution of Dr. Zhu has received research support from Chimerix Inc.
-
Dr. Esquenazi has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Zvavanjanja has nothing to disclose.
-
Miss Vu has nothing to disclose.
-
Ms. Schumann has received personal compensation for serving as an employee of Diakonos Oncology.
-
Mr. Trivedi has nothing to disclose.
-
Ms. Liu has nothing to disclose.
-
Mrs. Namekar has nothing to disclose.
-
Author has nothing to disclose
-
Mr. Ernste has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Mossop has nothing to disclose.
-
Dr. Clay has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for law firm. Dr. Clay has stock in investment portfolio.
-
Dr. Amin has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Kemnade has nothing to disclose.
-
Dr. Aguilar has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Diakonos Oncology. An immediate family member of Dr. Aguilar has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Candel Therapeutics. Dr. Aguilar has stock in Candel Therapeutics .
-
Dr. Turtz has received intellectual property interests from a discovery or technology relating to health care.
-
Nitin Tandon has stock in BrainDynamics. The institution of Nitin Tandon has received research support from NIH.
-
Dr. konduri has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Diakonos Oncology. Dr. konduri has stock in Diakonos Oncology. The institution of Dr. konduri has received research support from Diakonos Oncology.
-
Dr. Georges has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Decker has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Diakonos Oncology Corp.. Dr. Decker has stock in Diakonos Research, Ltd.. The institution of Dr. Decker has received research support from NIH. The institution of Dr. Decker has received research support from ALSF. The institution of Dr. Decker has received research support from Cancer Cures 4 Kids. Dr. Decker has received intellectual property interests from a discovery or technology relating to health care.